 Antiviral Agents
"Antiviral Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.
| Descriptor ID |
D000998
|
| MeSH Number(s) |
D27.505.954.122.388
|
| Concept/Terms |
Antiviral Agents- Antiviral Agents
- Agents, Antiviral
- Antivirals
- Antiviral Drugs
- Drugs, Antiviral
|
Below are MeSH descriptors whose meaning is more general than "Antiviral Agents".
Below are MeSH descriptors whose meaning is more specific than "Antiviral Agents".
This graph shows the total number of publications written about "Antiviral Agents" by people in this website by year, and whether "Antiviral Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 4 | 1 | 5 | | 1996 | 3 | 1 | 4 | | 1997 | 7 | 2 | 9 | | 1998 | 4 | 2 | 6 | | 1999 | 3 | 0 | 3 | | 2000 | 3 | 0 | 3 | | 2001 | 4 | 2 | 6 | | 2002 | 6 | 3 | 9 | | 2003 | 7 | 0 | 7 | | 2004 | 9 | 5 | 14 | | 2005 | 5 | 4 | 9 | | 2006 | 7 | 3 | 10 | | 2007 | 10 | 7 | 17 | | 2008 | 8 | 4 | 12 | | 2009 | 10 | 7 | 17 | | 2010 | 12 | 5 | 17 | | 2011 | 8 | 8 | 16 | | 2012 | 13 | 3 | 16 | | 2013 | 17 | 2 | 19 | | 2014 | 10 | 4 | 14 | | 2015 | 26 | 9 | 35 | | 2016 | 25 | 5 | 30 | | 2017 | 18 | 7 | 25 | | 2018 | 19 | 5 | 24 | | 2019 | 16 | 9 | 25 | | 2020 | 20 | 14 | 34 | | 2021 | 22 | 12 | 34 | | 2022 | 7 | 28 | 35 | | 2023 | 1 | 17 | 18 | | 2024 | 11 | 6 | 17 | | 2025 | 7 | 1 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Antiviral Agents" by people in Profiles.
-
Bassett HK, Rao S, Beck J, Brady PW, Jhaveri R, Joerger T, Liang D, Quinonez R, Shine A, Malec J, Lucas BP, Schroeder AR. Variability of Clinician Recommendations for Oseltamivir in Children Hospitalized With Influenza. Pediatrics. 2025 May 01; 155(5).
-
Chappell CA, Kiser JJ, Brooks KM, Randolph R, Macio IS, Meyn LA, MaWhinney S, Rick AM, Muniz GB, Kwon KM, Letterio C, Naik S, Kreter B, Bunge KE, Krans EE, Hillier SL. Sofosbuvir/Velpatasvir Pharmacokinetics, Safety, and Efficacy in Pregnant People With Hepatitis C Virus. Clin Infect Dis. 2025 Apr 30; 80(4):744-751.
-
Mahajan S, Kumar R, Singh A, Dhaka P, Pareek A, Kumar P, Tomar S. Targeting the host protein G3BP1 for the discovery of novel antiviral inhibitors against Chikungunya virus. Virology. 2025 Jul; 608:110551.
-
Rao M, Page RL, Sartain E. Twelve-Month Clinical and Cost Outcomes of Removal of Cytomegalovirus Intravenous Immune Globulin From Heart Transplantation Protocol. Clin Transplant. 2025 Apr; 39(4):e70147.
-
Ghoshal A, Tse EG, Hossain MA, Asressu KH, Merten EM, Sears JD, Howell S, Perveen S, Burdick J, Morales NL, Martinez SA, Law I, Davenport BJ, Morrison TE, Streblow ZJ, Streblow DN, Mordant AL, Webb TS, Cabrera A, Herring LE, Arrowsmith CH, Pearce KH, Moorman NJ, Heise MT, Cou?ago RM, Brown PJ, Willson TM. A covalent chemical probe for Chikungunya nsP2 cysteine protease with antialphaviral activity and proteome-wide selectivity. Sci Rep. 2025 Mar 01; 15(1):7264.
-
Torres TS, Saha PT, Smeaton L, Wimbish C, Kliemann DA, Avihingsanon A, Kityo C, Bennet JA, Van Schalkwyk M, Linas B, Nunes EP, Robbins GK, Wyles D, Naggie S, Sulkowski M, Cardoso SW, Solomon S. Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life. Qual Life Res. 2025 Jun; 34(6):1683-1694.
-
Singh A, Jangid K, Nehul S, Dhaka P, Rani R, Pareek A, Sharma GK, Kumar P, Tomar S. Structural and Mechanistic Insights into the Main Protease (Mpro) Dimer Interface Destabilization Inhibitor: Unveiling New Therapeutic Avenues against SARS-CoV-2. Biochemistry. 2025 04 01; 64(7):1589-1605.
-
Yin P, Sobolik EB, May NA, Wang S, Fayed A, Vyshenska D, Drobish AM, Parks MG, Lello LS, Merits A, Morrison TE, Greninger AL, Kielian M. Mutations in chikungunya virus nsP4 decrease viral fitness and sensitivity to the broad-spectrum antiviral 4'-Fluorouridine. PLoS Pathog. 2025 Jan; 21(1):e1012859.
-
Garzan A, Ahmed SK, Haese NN, Sulgey G, Medica S, Smith JL, Zhang S, Ahmad F, Karyakarte S, Rasmussen L, DeFilippis V, Tekwani B, Bostwick R, Suto MJ, Hirsch AJ, Morrison TE, Heise MT, Augelli-Szafran CE, Streblow DN, Pathak AK, Moukha-Chafiq O. 4-Substituted-2-Thiazole Amides as Viral Replication Inhibitors of Alphaviruses. J Med Chem. 2024 Dec 12; 67(23):20858-20878.
-
Ho K, Hoesley C, Anderson PL, Fern?ndez-Romero JA, Friedland BA, Kelly CW, Jiao Y, Edick S, Brand R, Kunjara Na Ayudhya RP, Zyhowski A, Hartman DJ, Reddy NB, Al-Khouja A, Piper J, Bauermeister JA, Teleshova N, Melo C, Cornejal N, Barnable P, Singh D, Scheckter R, McClure T, Hillier SL, Hendrix CW. Phase I Dose Volume Escalation of Rectally Administered PC-1005 to Assess Safety, Pharmacokinetics, and Antiviral Pharmacodynamics as a Multipurpose Prevention Technology (MTN-037). J Acquir Immune Defic Syndr. 2024 Dec 01; 97(4):379-386.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|